Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.
about
Human tumor antigens recognized by T lymphocytesImmunologic aspect of ovarian cancer and p53 as tumor antigen.T cell avidity and tumor recognition: implications and therapeutic strategies.Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerTargeted immune therapy of ovarian cancerFrom mice to humans: developments in cancer immunoeditingClinical applications of a peptide-based vaccine for glioblastoma.Gene therapy: development of immunostimulatory treatments for cancer.Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptideImmunity and immune suppression in human ovarian cancer.The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsPlasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.Combining radiotherapy and immunotherapy: a revived partnership.Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.Potential functional role of plasmacytoid dendritic cells in cancer immunity.Mobilizing the low-avidity T cell repertoire to kill tumors.Reengineering dendritic cell-based anti-cancer vaccines.Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.Can co-stimulated tumor immunity be therapeutically efficacious?Immunity to oncogenic proteins.A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.Tumor recognition by the cellular immune system: new aspects of tumor immunology.HLA and cancer: implications for cancer immunotherapy and vaccination.Induction of cytotoxic T lymphocytes to murine mammary tumor cells with a Kd-restricted immunogenic peptide.
P2860
Q24678508-A72DBE7F-9A0F-4634-BF30-A126C80E2644Q24814703-35015380-0646-4D29-908B-F3FFC7C0065BQ24815775-E9E186F8-ED32-492D-8FEC-512A67456025Q26996829-7C18DCE6-93C5-4506-986D-A06CD825EC66Q28082828-23DE18D2-CE59-4722-B8E4-91DD8F6B798CQ28088304-B3445DED-D735-4082-A3A8-C6E0BF4CC756Q33668575-B5936FE1-CD78-4C25-8FDE-2444606805D7Q34187915-EC66F440-3607-484C-BB6B-9D2C5E09F8BEQ34493886-4D22EFF3-EAFF-4CB2-BC57-FEB554CC03BCQ34765735-38E018FB-FC0F-4DB4-90B4-D64504DDEAC8Q35138135-69B2EB12-68CB-48AB-A8C2-14A6A0127E82Q35181440-E9F473D5-F91D-428D-99A6-6A380ADD9780Q36011425-607F320F-2DC3-4FE7-BC50-82DB5EF99E17Q36198661-57EA2FCD-19EC-4AA2-9373-4188F9BE8907Q36274581-2326FD02-E5F5-402B-A7F8-FC65634615F7Q36364998-D6D6DEB8-4CBD-4719-B01F-DF1C53BBE960Q36764252-A159CF40-36EB-4E4D-B09E-CCF577A9972CQ36891310-8C9FEDA9-35EB-4948-9107-2471E7832F96Q37118177-2E0A22A9-5EDB-4FD0-AFC1-B5650AF43D12Q37412304-4C5891A9-68BD-4CE8-B86F-2686097F5ADEQ40433269-AFC436E4-5C13-425E-A0DD-0E5E198F1671Q40433308-786002F8-C90A-4665-BD4F-D4F4B4C2D61AQ40840298-0FE1D658-497C-4DC0-AD44-DFD830E76CEEQ40953949-83EB8C4C-015B-4BB7-9570-09D9D988F6E9Q41455911-F41AB5D3-CD7A-4D91-A515-DEBC453A022BQ41599028-25F02229-D40A-487E-9DF3-E47462306BD6Q44388164-797A8F96-4D4B-48E3-B13C-E5C3F96D8716
P2860
Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Cytotoxic T cells isolated fro ...... the HER-2/neu proto-oncogene.
@en
type
label
Cytotoxic T cells isolated fro ...... the HER-2/neu proto-oncogene.
@en
prefLabel
Cytotoxic T cells isolated fro ...... the HER-2/neu proto-oncogene.
@en
P2093
P356
P1433
P1476
Cytotoxic T cells isolated fro ...... the HER-2/neu proto-oncogene.
@en
P2093
P304
P356
10.1006/CIMM.1993.1233
P577
1993-10-01T00:00:00Z